![Wladimir Hogenhuis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wladimir Hogenhuis
Directeur/Membre du Conseil chez
REZOLUTE, INC.
Fortune : 394 928 $ au 31/05/2026
Profil
Wladimir Hogenhuis currently works at Driver Bioengineering, Inc., as President, Chief Executive Officer & Director from 2022, Rezolute, Inc., as Independent Director from 2021, GATT Technologies BV, as Director from 2020, and IHP Therapeutics, Inc., as Director.
Mr. Hogenhuis also formerly worked at Vision 2020, as Director, Merck & Co., Inc., as General Manager-Neuroscience, Ultragenyx Pharmaceutical, Inc., as Chief Operating Officer from 2018 to 2020, and GSK Plc, as Senior Vice President from 2012 to 2018.
Mr. Hogenhuis received his doctorate degree from the University of Leiden and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
REZOLUTE, INC. 0,14% | 16/12/2025 | 119 675 ( 0,14% ) | 394 928 $ | 31/05/2026 |
Postes actifs de Wladimir Hogenhuis
| Sociétés | Poste | Début |
|---|---|---|
| REZOLUTE, INC. | Directeur/Membre du Conseil | 02/03/2021 |
GATT Technologies BV
 GATT Technologies BV Medical SpecialtiesHealth Technology Develops a soluble surgical tape | Directeur/Membre du Conseil | 01/05/2020 |
IHP Therapeutics, Inc. | Directeur/Membre du Conseil | - |
Driver Bioengineering, Inc.
 Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor | Directeur Général | 28/04/2022 |
Anciens postes connus de Wladimir Hogenhuis
| Sociétés | Poste | Fin |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Directeur des opérations | 10/01/2020 |
| GSK PLC | Corporate Officer/Principal | 01/09/2018 |
Vision 2020 | Directeur/Membre du Conseil | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Formation de Wladimir Hogenhuis
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
55
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University of Leiden
 University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vision 2020 | |
Rezolute, Inc.
 Rezolute, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for metabolic diseases related to chronic glucose imbalance | Health Technology |
GATT Technologies BV
GATT Technologies BV Medical SpecialtiesHealth Technology Develops a soluble surgical tape | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Driver Bioengineering, Inc.
Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor | Health Technology |
IHP Therapeutics, Inc. |
